Maximizing neuroprotection: where do we stand?

被引:11
作者
Kuffler, Damien P. [1 ]
机构
[1] Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA
来源
THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2012年 / 8卷
关键词
adenosine; hypothermia; alkalinization; glucocorticoids; SPINAL-CORD-INJURY; RETROGRADE VENOUS PERFUSION; ADENOSINE A(2A) AGONIST; CULTURED HIPPOCAMPAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; RAT SENSORY NEURONS; CELL-DEATH; IN-VITRO; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA;
D O I
10.2147/TCRM.S16196
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Brain and spinal cord traumas include blunt and penetrating trauma, disease, and required surgery. Such traumas trigger events such as inflammation, infiltration of inflammatory and other cells, oxidative stress, acidification, excitotoxicity, ischemia, and the loss of calcium homeostasis, all of which cause neurotoxicity and neuron death. To prevent trauma-induced neurological deficits and death, each of the many neurotoxic events that occur in parallel or sequentially must be minimized or prevented. Although neuroprotective techniques have been developed that block single neurotoxic events, most provide only limited neuroprotection and are only applied singly. However, because many neurotoxicity triggers arise from common events, an approach for invoking more effective neuroprotection is to apply multiple neuroprotective methods simultaneously before the many neurotoxic triggers and cascades are initiated and become irreversible. This paper first discusses some triggers of neurotoxicity and neuroprotective mechanisms that block them, including hypothermia, alkalinization, and the administration of adenosine. It then examines how the simultaneous application of these techniques provides significantly greater neuroprotection than is provided by any technique alone. The paper also stresses the importance of determining whether the neuroprotection provided by these techniques can be further enhanced by combining them with additional techniques, such as the systemic administration of glucocorticoids. Finally, the paper stresses the absolute critical importance of applying these techniques within the "golden hour" following trauma, before the many neurotoxic events and cascades are manifest and before the neurotoxic cascades become irreversible.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 50 条
  • [41] Gene Therapy for Chronic Neuropathic Pain: How Does It Work and Where Do We Stand Today?
    Kumar, Sanjeev
    Ruchi, Rupam
    James, Stephen R.
    Chidiac, Elie J.
    PAIN MEDICINE, 2011, 12 (05) : 808 - 822
  • [42] Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?
    Mathey, G.
    Michaud, M.
    Pittion-Vouyovitch, S.
    Debouverie, M.
    REVUE NEUROLOGIQUE, 2018, 174 (06) : 378 - 390
  • [43] The role of nanochitin in biologically-active matrices for tissue engineering-where do we stand?
    Olza, Sheila
    Salaberria, Asier M. M.
    Alonso-Varona, Ana
    Samanta, Ayan
    Fernandes, Susana C. M.
    JOURNAL OF MATERIALS CHEMISTRY B, 2023, 11 (25) : 5630 - 5649
  • [44] Evidence from systematic reviews on photobiomodulation of human bone and stromal cells: Where do we stand?
    Parenti, Serena Incerti
    Tschon, Matilde
    Sartori, Maria
    Visani, Andrea
    Aroni, Elena
    Fini, Milena
    Alessandri-Bonetti, Giulio
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 685
  • [45] Minimization vs tailoring:Where do we stand with personalized immunosuppression during renal transplantation in 2015?
    Lajos Zsom
    László Wagner
    Tibor Fül?p
    World Journal of Transplantation, 2015, 5 (03) : 73 - 80
  • [46] LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
    Taymans, Jean-Marc
    Greggio, Elisa
    CURRENT NEUROPHARMACOLOGY, 2016, 14 (03) : 214 - 225
  • [47] Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
    Karpel-Massler, Georg
    Schmidt, Ursula
    Unterberg, Andreas
    Halatsch, Marc-Eric
    MOLECULAR CANCER RESEARCH, 2009, 7 (07) : 1000 - 1012
  • [48] Uterine Tissue Engineering: Where We Stand and the Challenges Ahead
    Almeida, Gustavo Henrique DonaRodrigues
    Iglesia, Rebeca Piatniczka
    Araujo, Michelle Silva
    Carreira, Ana Claudia Oliveira
    dos Santos, Erika Xavier
    Calomeno, Celso Vitor Alves Queiroz
    Miglino, Maria Angelica
    TISSUE ENGINEERING PART B-REVIEWS, 2022, 28 (04) : 861 - 890
  • [49] Autoantibodies and Malaria: Where We Stand? Insights Into Pathogenesis and Protection
    Mourao, Luiza Carvalho
    Cardoso-Oliveira, Gustavo Pereira
    Braga, Erika Martins
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [50] The emerging role of artificial intelligence in neuropathology: Where are we and where do we want to go?
    Broggi, Giuseppe
    Mazzucchelli, Manuel
    Salzano, Serena
    Barbagallo, Giuseppe Maria Vincenzo
    Certo, Francesco
    Zanelli, Magda
    Palicelli, Andrea
    Zizzo, Maurizio
    Koufopoulos, Nektarios
    Magro, Gaetano
    Caltabiano, Rosario
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263